Chlorhexidine Gluconate Solution at 0.125% vs Placebo for the Healing of Grade IIB Ulcers of Diabetic Foot

March 13, 2019 updated by: Jose Antonio de Jesus Alvarez Canales, Universidad de Guanajuato

Standard Management and Chlorhexidine Gluconate Solution at 0.125% Versus Standard Management and Physiological Saline Sterile Solution for Healing Grade IIB Ulcers in Diabetic Foot Syndrome: Clinical Trial

There is controversy regarding the utility of antiseptics in wound management for diabetic foot ulcer syndrome. The aim of this study is to assess chlorhexidine gluconate at 0.125% vs. saline solution to reduce the ulcerated area in patients with diabetic ulcer syndrome. A clinical trial model to evaluate modifications in size and area is proposed. Patients to be included will be those with diabetic foot ulcers Graded II accordingly to the University of Texas wound classification system.

Study Overview

Detailed Description

This study will be done in Hospital General de Leon

Population: People with diabetic foot syndrome grade IIb in Guanajuato Mexico

Universe: People with diabetes mellitus and diabetic foot syndrome in Guanajuato

Sample: Patients with diabetes mellitus over age of 18 years old, that present to the wound´s clinic of Hospital General Leon with diabetic foot ulcers classified as Texas IIB. This clinic provides services to patients in Guanajuato with diabetic foot syndrome, including them in a multidisciplinary management program.

Sample size calculation: A minimal sample of 35 patients for each arm of the study was calculated. Each study arm will be balanced considering the size. Potency was calculated at 0.8 and alpha value at 0-5, to detect a difference of 25% on the ulcer size.

Methodology:

Will be invited to participate in the study consecutive patients with diabetes mellitus presented with diabetic foot ulcers Graded II accordingly to the University of Texas wound classification system, in the area of Clinical wounds of Hospital General Leon between May and December 2017.

After explaining the study information and check it is understandable, the investigators provide the sheet to signed the informed consent.

Subsequently selected patients will be measure the ankle brachial index and determine the absence of vascular compromise.

Medical history with emphasis on analyzing clinical data, including the characteristics of the ulcer (type of exudate, measured surface area affected , type of tissue involved in the ulcer to its depth ) and biochemical parameters will be made.

Patients will be weighed and measured at the first visit and those who don't have biochemical data will be requested to collect this information in subsequent follow-up visits.

The participants will be then treated with the principles of the standard treatment, under the following criteria:

  • Remove the ulcer exudate by spraying one of the two ingredients making mechanical drive for 5 minutes, or until completely negative to the visual evidence of exudate.
  • Completely remove hyperkeratosis and devitalized tissue from the periphery of the ulcer with cutting material dissection with sterile dressing and drag, until visually eliminate the exudate.
  • The treated area is dried.
  • Two photographs at a distance of 20 cm perpendicular to the ulcer will be taken, covering a 1 square centimeter reference for measuring the area affected by diabetic foot ulcer syndrome.
  • The solution will be applied in a blinded way to the ulcer and covered with sterile gauze for 24 hours.
  • The patient will be instructed to continue treatment every 24 hours as follows:
  • Sterile gauze will be removed and continuously irrigate for 5 seconds with the ingredient that was assigned.
  • Undiscovered for 24 hours, until the next day irrigation gauze area will be placed. Also need to avoid contact with any surface over the affected area until the next assessment.
  • Perform the same strategy for 24 hours, and on day 7 must go to the wound clinic to clinical evaluation.
  • Every 7 days until complete 6 views, clinical evaluation is performed, irrigation with the selected ingredient and it will take 2 pictures at a distance of 20 cm perpendicular to the ulcer again, covering a reference of 1 square centimeter to measure the area affected by the diabetic foot ulcer syndrome.

Every week during the following 6 weeks, in the wound clinic consultation, it will be measured and gather information of the following elements:

  • Ulcer area in square millimeters.
  • Color of the ulcer.
  • Type of exudate; turbid, serous.
  • Type of tissue involved in the ulcer to its depth. If any patients have increased intensity of the signs and symptoms of diabetic foot syndrome, classified as a major step on the scale of ulcers Classification System of the University of Texas, perform analysis and comprehensive treatment will be redefined according to the suggestions of ulcer classification system of the University of Texas.

Cleaning material for the ulcer:

Ingredient 1: Preparation of spray application of chlorhexidine gluconate 0.125%.

Ingredient 2: Preparation of spray application of physiological saline sterile solution.

Method of application of ingredients as described previously. Method of randomization: will be effected since the fabrication of the ingredient by assigning a code number to each of the bottles that contained. Those bottles will have identical presentations, and will balance for the sample size. The code will not be known by the patient, observer and analyst. Only be known by one of the advisors.

Statistical methods:

The description of the data, in the case of non-numerical variables will be performed by reporting proportions and confidence interval of 95 % (95 %) in the case of numerical variables, the description will be made based on averages and standard deviation or medians and Q1- Q3 range, depending on the result of the Kolmogorov-Smirnov test to evaluate the Gaussian distribution of the data.

Comparison of numerical variables were not performed by Chi square test. Comparison of the rates of reduction in the size of ulcers of diabetic foot syndrome for both treatments will be based on the t test for independent samples or by Kruskal- Wallis test, depending on data distribution.

In all cases be considered as the significance level alpha value <0.05.

Study Type

Interventional

Enrollment (Anticipated)

35

Phase

  • Phase 4

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Guanajuato
      • Leon, Guanajuato, Mexico, 37320
        • Recruiting
        • Universidad de Guanajuato
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

16 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Ambulatory patients of both sex over age of 18 years old with diabetes mellitus that present an ulcer caused by diabetic foot syndrome with an extension from skin to tendon or join capsule and infected, classified as Texas IIB.

Exclusion Criteria:

  • Patients lost to follow up and those that voluntary leave the study.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Quadruple

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Standard management and Chlorhexidine gluconate at 0.125%
Application every 24 hours, six weeks Intervention: Procedure: chlorhexidine gluconate
Application every 24 hours, six weeks Intervention: Procedure: chlorhexidine gluconate
Placebo Comparator: Standard management and physiological saline sterile solution
Application every 24 hours, six weeks Intervention: Other: physiological saline sterile solution
Standard management and physiological saline sterile solution with application every 24 hours, six weeks Intervention.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Ulcerated area
Time Frame: Up to 6 weeks
area of diabetic foot ulcer measured with photographic register using a visual control of dimensions and a dedicated software for measurements.
Up to 6 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Study Director: Alejandro E Macias, MD, Universidad de Guanajuato

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

May 11, 2017

Primary Completion (Anticipated)

December 15, 2020

Study Completion (Anticipated)

December 30, 2020

Study Registration Dates

First Submitted

July 1, 2017

First Submitted That Met QC Criteria

July 5, 2017

First Posted (Actual)

July 6, 2017

Study Record Updates

Last Update Posted (Actual)

March 15, 2019

Last Update Submitted That Met QC Criteria

March 13, 2019

Last Verified

March 1, 2019

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

No

IPD Plan Description

None IPD will be share; only group data analyzed

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Diabetic Foot

Clinical Trials on Chlorhexidine gluconate at 0.125%

3
Subscribe